{
  "docId": "019dd923-5fed-74f2-a96f-364382cb2b75",
  "docSlug": "bi-dc35af3bd0eea4cf",
  "documentTitle": "HMNC Brain Health pitch deck: $14 million for precision treatments",
  "authorId": "Pitchdecks",
  "authorName": "HMNC Brain Health",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.777,
  "pageNumber": 10,
  "pageCount": 12,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "traction",
  "function": "show_traction",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Mentions Sanofi partnership/asset acquisition context.",
  "elementsJson": [
    "headline_text",
    "action_title",
    "logo_grid",
    "paragraph",
    "numbered_list",
    "icon_grid"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5fed-74f2-a96f-364382cb2b75/10",
  "deckHref": "/decks/019dd923-5fed-74f2-a96f-364382cb2b75",
  "deckJsonHref": "/decks/019dd923-5fed-74f2-a96f-364382cb2b75.json",
  "deckAnchorHref": "/decks/019dd923-5fed-74f2-a96f-364382cb2b75#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "callout",
      "text": "OLIVE, our multicenter, double-blind, randomized, placebo-controlled phase II trial with BH-200 & V1bCDx",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bf89c34c-de74-4606-98cc-c9ad18b45306",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "image",
      "text": "Sanofi",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "afaf283b-621f-4bb0-add9-a72a70a9e478",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.4,
        "x": 0.55,
        "y": 0.55
      },
      "kind": "list",
      "text": "Outpatients with MDD\n8-week monotherapy with BH-200 (250 mg BID)\n324 patients randomized\nMultinational CRO-led\nFirst patients randomized in H1 2023\nRead-out expected in H2 2024",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19464915-996f-47ea-8cf5-e8c11a577799",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.38
      },
      "kind": "list",
      "text": "1. Assess the efficacy of BH-200 vs. placebo in improving depressive symptoms in V1bCDx-positive patients\n2. Assess the efficacy of BH-200 inV1bCDx-positive vs. V1bCDx-negative patients in improving depressive symptoms",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2e8ccb8-e364-4972-92fa-98df249c89ab",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "patients randomized: 324",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-cb16-77cb-9961-f32089479072",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "paragraph",
      "text": "BH-200 (nelivaptan) is a V1b receptor antagonist that was previously under development for Sanofi for psychiatry indications. Clinical trials in over 900 subjects suggest that BH-200 is generally safe and well-tolerated, thereby de-risking its further clinical development. Our flagship phase 2 randomized clinical trial (OLIVE), testing both BH-200 and the CDx, should give proof-of-concept of our precision psychiatry approach.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "34fa6b3a-dca9-4294-a277-06eb6d902d56",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "OLIVE, HMNC’S FIRST RANDOMIZED CLINICAL TRIAL CONFIRMING THE PRECISION PSYCHIATRY APPROACH",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40042778-b73f-4a1e-88d3-cfe3fe87fed3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 10,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "723e4b79-0471-4e54-9684-ccd3140a0b94",
      "evidence": "Problem statement and traction",
      "position": 0,
      "objective": "Highlighting the cost of not adopting precision psychiatry",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 10,
      "from": 8,
      "name": "Why Now",
      "slug": "15-why-now",
      "bestFor": "Sales pitches, fundraising, requesting immediate budget approval",
      "matchId": "77608a65-a053-4cbb-bd44-0999621d3ce8",
      "evidence": "Co-development pipeline and traction",
      "position": 1,
      "objective": "Explaining the timeliness of the investment opportunity",
      "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity",
      "confidence": 0.6,
      "description": "Create temporal urgency by proving that the window of opportunity is opening or closing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}